scholarly journals Evaluation of Plasma Soluble Urokinase Plasminogen Activator Receptor Levels in Patients With COVID-19 and Non-COVID-19 Pneumonia: An Observational Cohort Study

2021 ◽  
Vol 13 (9) ◽  
pp. 474-478
Author(s):  
Dimitrios Velissaris ◽  
Maria Lagadinou ◽  
Themistoklis Paraskevas ◽  
Eleousa Oikonomou ◽  
Vasileios Karamouzos ◽  
...  
Keyword(s):  
Cohort Study ◽  
Plasminogen Activator ◽  
Urokinase Plasminogen Activator ◽  
Observational Cohort Study ◽  
Urokinase Plasminogen Activator Receptor ◽  
Observational Cohort ◽  
Plasminogen Activator Receptor

Soluble urokinase plasminogen activator receptor and incidence of venous thromboembolism

2016 ◽  
Vol 115 (03) ◽  
pp. 657-662 ◽  
Author(s):  
Bengt Zöller ◽  
Peter J. Svensson ◽  
Olle Melander ◽  
Margaretha Persson ◽  
Gunnar Engström
Keyword(s):  
Cohort Study ◽  
Venous Thromboembolism ◽  
Plasminogen Activator ◽  
Urokinase Plasminogen Activator ◽  
Population Based ◽  
Risk Indicator ◽  
Urokinase Plasminogen Activator Receptor ◽  
Plasminogen Activator Receptor ◽  
Incident Cases

SummaryRaised plasma levels of the soluble urokinase plasminogen activator receptor (suPAR) have been associated with increased incidence of cardiovascular diseases. Whether suPAR is associated with venous thromboembolism (VTE) is largely unknown. The purpose of the present study was to investigate the relationship between suPAR and incidence of VTE in a cohort study. suPAR was measured in 5,203 subjects (aged 46–68 years, 58 % women) from the general population, who participated in the Malmö Diet and Cancer (MDC) study between 1991 and 1994. Incident cases of VTE were identified from the Swedish patient register during a mean follow-up of 15.7 years. Of 5,203 subjects with measurements of suPAR, 239 had VTE during follow-up (127 venous thrombosis, 86 lung embolism, 26 both). Incidence of VTE was significantly higher in subjects with suPAR levels in the top quartile. Adjusted for age and sex, the HR (4th vs 1st quartile) was 1.74 (95%CI: 1.2–2.6, p for trend=0.003). After adjustments for risk factors, the HR was 1.66 (95 %CI: 1.1–2.5, p for trend=0.016). High level of suPAR was a risk indicator for incidence of VTE in this population-based cohort study. The causal relationships between suPAR and VTE remain to be explored.Supplementary Material to this article is available online at www.thrombosis-online.com.

scholarly journals Soluble urokinase plasminogen activator receptor and lactate as prognostic biomarkers in patients presenting with non-specific chief complaints in the pre-hospital setting – the PRIUS-study

2021 ◽  
Vol 29 (1) ◽  
Author(s):  
Robert Ivic ◽  
Jouni Nurmi ◽  
Lisa Kurland ◽  
Veronica Vicente ◽  
Veronica Lindström ◽  
...  
Keyword(s):  
Plasminogen Activator ◽  
Vital Signs ◽  
Hospital Setting ◽  
Positive Likelihood Ratio ◽  
Urokinase Plasminogen Activator ◽  
Urokinase Plasminogen Activator Receptor ◽  
Chief Complaints ◽  
Observational Cohort ◽  
Plasminogen Activator Receptor ◽  
National Emergency

Abstract Background Emergency Medical Services (EMS) are faced daily with patients presenting with non-specific chief complaints (NSC). Patients presenting with NSCs often have normal vital signs. It has previously been established that NSCs may have a serious underlying condition that has yet to be identified. The aim of the current study was to determine if soluble urokinase plasminogen activator receptor (suPAR) and lactate could be used to identify serious conditions among patients presenting with NSCs to the EMS. The secondary aim was to describe the prognostic value for mortality in the group. Method A blinded prospective observational cohort study was conducted of patients brought to the ED by ambulance after calling the national emergency number 112 and who were assessed as having NSC by the EMS. Biomarkers were measured during index EMS assessment before transportation to the ED. Patients were followed via EMS and hospital electronic health records. Descriptive and logistic regression analyses were used. Results A total of 414 patients were included, with a median age of 82 years. A serious condition was present in 15.2% of the patients. Elevated suPAR above 3 ng/ml had a positive likelihood ratio (LR+) of 1.17 and a positive predictive value (PPV) of 17.3% as being predictive of a prevalent serious condition. Elevated suPAR above 9 ng/ml had LR+ 4.67 and a PPV of 16.7% as being predictive of 30-day mortality. Lactate was not significantly predictive. Conclusion Pre-hospital suPAR and lactate cannot differentiate serious conditions in need of urgent treatment and assessment in the ED among patients presenting with non-specific chief complaints. suPAR has shown to be predictive of 30-day mortality, which could add some value to the clinical assessment. Trial registration NCT03089359. Registered 20 March 2017, retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT03089359.

Sign in / Sign up

Export Citation Format

Share Document